Government-Owned Inventions; Availability for Licensing, 9521-9522 [2021-03044]
Download as PDF
<![CDATA[
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
Dated: February 9, 2021.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03015 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meetings
khammond on DSKJM1Z7X2PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Pediatric Formulations of
Select Second Line Drugs for Treating
Tuberculosis (Topic 97).
Date: February 22, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892, 240–669–5199,
cerritem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase I: Pediatric Formulations of
Select Second Line Drugs for Treating
Tuberculosis (Topic 96).
Date: February 24, 2021.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892, 240–669–5199,
cerritem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; HHS–NIH–CDC–SBIR PHS
2021–1 Phase II: Pediatric Formulations of
Select Second Line Drugs for Treating
Tuberculosis (Topic 97).
Date: February 24, 2021.
Time: 4:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Mario Cerritelli, Ph.D.,
Scientific Review Officer, Scientific Review
Program, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F58,
Rockville, MD 20892, 240–669–5199,
cerritem@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: February 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03016 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
SUMMARY:
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
9521
FOR FURTHER INFORMATION CONTACT:
Chris Kornak at 240–627–3705 or
Chris.Kornak@nih.gov. Licensing
information may be obtained by
communicating with the Technology
Transfer and Intellectual Property
Office, National Institute of Allergy and
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished information
related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
Replication-Competent Adenovirus
Type 4 SARS–CoV–2 Vaccines and
Their Use
Description of Technology
NIAID has produced recombinant
adenovirus type 4 (Ad4), SARS–CoV–2
spike, vectors for administration to
humans. These recombinant vaccines
permit rapid development of high levels
of neutralizing antibodies to SARS–
CoV–2 in experimental animals. This
vaccine is designed to improve the
durability of the immune response by
inducing mucosal and systemic
immunity. Further, this system should
be incredibly simple and efficient when
producing vaccine at scale. This
technology is available for licensing for
commercial development in accordance
with 35 U.S.C. 209 and 37 CFR part 404,
as well as for further development and
evaluation under a research
collaboration.
Potential Commercial Applications
• Vaccine composition(s)
Competitive Advantages
• Stimulates a durable immune
response;
• Induction of mucosal and systemic
immunity;
• Potential for transmission
interruption;
• Intranasal administration minimizes
the impact of pre-existing immunity;
• Notable improvement for
manufacturing yield and cost, ease of
administration, and distribution as
compared to current candidates.
Inventor: Mark Connors, M.D. (NIAID)
Publications: Matsuda et al. Journal of
Clinical Investigation, 2021. (https://
doi.org/10.1172/JCI140794). Matsuda et
al., Science Immunology 2019 (https://
doi.org/10.1126/sciimmunol.aau2710).
Intellectual Property: HHS Reference
E–055–2021; Application No. 63/
138,221.
Licensing Contact: To license this
technology, please contact Chris Kornak
at chris.kornak@nih.gov.
E:\FR\FM\16FEN1.SGM
16FEN1
9522
Federal Register / Vol. 86, No. 29 / Tuesday, February 16, 2021 / Notices
Collaborative Research Opportunity:
The National Institute of Allergy and
Infectious Diseases is seeking statements
of capability or interest from parties
interested in collaborative research to
further develop, evaluate or
commercialize this invention. Interested
parties should have the ability to
manufacture viruses under cGMP,
suitable for Phase 1–2 testing by NIAID.
Capabilities for further clinical
development, and experience with
Phase 3 testing, licensure, and rollout
are preferred. For collaboration
opportunities, please contact Chris
Kornak at chris.kornak@nih.gov.
Dated: January 29, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2021–03044 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
khammond on DSKJM1Z7X2PROD with NOTICES
Notice is hereby given of a meeting of
the HEAL (Helping to End Addiction
Long-term) Multi-Disciplinary Working
Group
The meeting will be open to the
public as indicated below via NIH
Videocast. Individuals who need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The program documents
and the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the program
documents, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: HEAL MultiDisciplinary Working Group Meeting.
Date: March 2–3, 2021.
Open: March 02, 2021, 11:00 a.m. to 12:20
p.m.
Closed: March 02, 2021, 12:20 p.m. to 4:30
p.m.
Open: March 03, 2021, 10:30 a.m. to 11:05
a.m.
Closed: March 03, 2021, 11:05 a.m. to 2:45
p.m.
VerDate Sep<11>2014
17:04 Feb 12, 2021
Jkt 253001
Agenda: Provide an update on Helping to
End Addiction Long-Term (HEAL) Initiative
projects and obtain expertise from MDWG
relevant to the NIH HEAL Initiative and to
specific HEAL projects.
Videocast: The open portion of the meeting
will be live webcast at: https://
videocast.nih.gov/.
Place: National Institutes of Health
Building 1, Wilson Hall, 1 Center Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Rebecca G Baker, Ph.D.,
Office of the Director, National Institutes of
Health, 1 Center Drive, Room 103A,
Bethesda, MD 20892, (301) 402–1994,
Rebecca.baker@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the Office
of the Director for the NIH HEAL Initiative
home page: https://heal.nih.gov/news where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.853, Clinical Research
Related to Neurological Disorders; 93.854,
Biological Basis Research in the
Neurosciences, National Institutes of Health,
HHS)
Dated: February 9, 2021.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2021–03018 Filed 2–12–21; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Notice of Diabetes Mellitus Interagency
Coordinating Committee Meeting
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The Diabetes Mellitus
Interagency Coordinating Committee
(DMICC) will hold a meeting on March
3, 2021. The topic for this meeting will
be ‘‘COVID–19 and Diabetes.’’ The
meeting is open to the public.
DATES: The meeting will be held on
March 3, 2021 from 12 noon to 4:00
p.m. EST.
ADDRESSES: The meeting will be held
via the online video conferencing—
Zoom. For details, and to register, please
contact dmicc@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT: For
further information concerning this
meeting, including a draft agenda, see
the DMICC website,
www.diabetescommittee.gov, or contact
SUMMARY:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
Dr. B. Tibor Roberts, Executive
Secretary of the Diabetes Mellitus
Interagency Coordinating Committee,
National Institute of Diabetes and
Digestive and Kidney Diseases, 31
Center Drive, Building 31A, Room
9A19, MSC 2560, Bethesda, MD 20892–
2560, telephone: 301–496–6623; FAX:
301–480–6741; email: dmicc@
mail.nih.gov.
In
accordance with 42 U.S. Code 285c–3,
the DMICC, chaired by the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) comprising
members of the Department of Health
and Human Services and other federal
agencies that support diabetes-related
activities, facilitates cooperation,
communication, and collaboration on
diabetes among government entities.
DMICC meetings, held several times a
year, provide an opportunity for
Committee members to learn about and
discuss current and future diabetes
programs in DMICC member
organizations and to identify
opportunities for collaboration. The
March 3, 2021 DMICC meeting will
focus on ‘‘COVID–19 and Diabetes.’’
Any member of the public interested
in presenting oral comments to the
Committee should notify the contact
person listed on this notice at least 5
days in advance of the meeting.
Interested individuals and
representatives or organizations should
submit a letter of intent, a brief
description of the organization
represented, and a written copy of their
oral presentation in advance of the
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
meeting, oral comments will be allowed
on a first-come, first-serve basis.
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
website, www.diabetescommittee.gov.
SUPPLEMENTARY INFORMATION:
E:\FR\FM\16FEN1.SGM
16FEN1
]]>Agencies
[Federal Register Volume 86, Number 29 (Tuesday, February 16, 2021)]
[Notices]
[Pages 9521-9522]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-03044]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Chris Kornak at 240-627-3705 or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Replication-Competent Adenovirus Type 4 SARS-CoV-2 Vaccines and Their
Use
Description of Technology
NIAID has produced recombinant adenovirus type 4 (Ad4), SARS-CoV-2
spike, vectors for administration to humans. These recombinant vaccines
permit rapid development of high levels of neutralizing antibodies to
SARS-CoV-2 in experimental animals. This vaccine is designed to improve
the durability of the immune response by inducing mucosal and systemic
immunity. Further, this system should be incredibly simple and
efficient when producing vaccine at scale. This technology is available
for licensing for commercial development in accordance with 35 U.S.C.
209 and 37 CFR part 404, as well as for further development and
evaluation under a research collaboration.
Potential Commercial Applications
Vaccine composition(s)
Competitive Advantages
Stimulates a durable immune response;
Induction of mucosal and systemic immunity;
Potential for transmission interruption;
Intranasal administration minimizes the impact of pre-existing
immunity;
Notable improvement for manufacturing yield and cost, ease of
administration, and distribution as compared to current candidates.
Inventor: Mark Connors, M.D. (NIAID)
Publications: Matsuda et al. Journal of Clinical Investigation,
2021. (https://doi.org/10.1172/JCI140794). Matsuda et al., Science
Immunology 2019 (https://doi.org/10.1126/sciimmunol.aau2710).
Intellectual Property: HHS Reference E-055-2021; Application No.
63/138,221.
Licensing Contact: To license this technology, please contact Chris
Kornak at [email protected]
[[Page 9522]]
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate or commercialize this invention. Interested parties
should have the ability to manufacture viruses under cGMP, suitable for
Phase 1-2 testing by NIAID. Capabilities for further clinical
development, and experience with Phase 3 testing, licensure, and
rollout are preferred. For collaboration opportunities, please contact
Chris Kornak at [email protected]
Dated: January 29, 2021.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-03044 Filed 2-12-21; 8:45 am]
BILLING CODE 4140-01-P
